Petros Pharmaceuticals, Inc. (PTPI)
|Net Income (ttm)||-20.59M|
|Trading Day||May 12|
|Day's Range||3.00 - 3.35|
|52-Week Range||1.80 - 5.96|
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the ...
NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovati...
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused...
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.
It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study update from eve...
Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) ...
Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.
Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.
Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.
The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.
Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting late-stage...
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, PTPI's revenue was $9.56 million, a decrease of -38.63% compared to the previous year's $15.58 million. Losses were -$20.59 million, -36.68% less than in 2019.